Sydney, Australia 21 February 2018 – Clarity Pharmaceuticals, an Australian radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that Professor Andreas Kjaer has joined their scientific advisory board. Andreas Kjaer is a professor at the University of Copenhagen and is chief physician and head of research at the Department of Clinical Physiology, Nuclear Medicine & PET at Rigshospitalet, the National University Hospital of Denmark.
Professor Kjaer is one of the world leaders in the field of molecular imaging with PET and PET/MRI and targeted radionuclide therapies (theranostics). Achievements include development of several new tracers that have reached first-in-human clinical use.
He is the holder of an ERC advanced grant. He is a former president of the Scandinavian Society of Clinical Physiology and Nuclear Medicine (SSCPNM) and served on the Scientific Committee of the Danish Cancer Society. Currently, he is a member of the European Association of Nuclear Medicine (EANM) Oncology Committee, member of the advisory board of the European Neuroendocrine Tumor Society (ENETS) and national representative for the European Society for Molecular Imaging (ESMI). Professor Kjaer is also Editor-in-Chief of Diagnostics (Basel), head of the Cluster for Molecular Imaging and director of the Postgraduate School for Medical and Molecular Imaging at the Faculty of Health Sciences, University of Copenhagen.
Professor Kjaer commented on his appointment “I am very excited about joining Clarity’s scientific advisory board at this time. The industry in recent years has been growing significantly and Clarity, with its proprietary technology for the use of copper for diagnostics and therapy, is well positioned to capitalise on this. My own research with copper-64 as a PET agent has given me great confidence for the broad use of copper as an imaging agent, especially compared with gallium-68 that has a number of physical and logistical challenges when it comes to broader clinical application. Coupled with an ideal therapeutic pairing, I’m looking forward to working closely with the company to explore a number of diagnostic and therapeutic options.”
Clarity’s Executive Chairman Dr Alan Taylor added “We are very excited to have Andreas on our scientific board and believe that his expertise in radiopharmaceutical development will be invaluable for the progression of our current assets in development. His extensive experience with copper-64, understanding of the clear benefits of copper-64 compared to gallium-68 as a PET agent, and central European location allows us to now combine European expansion with our current efforts in the US and Asia Pacific regions. ”
About Clarity
Clarity Pharmaceuticals is a personalised medicine company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceutical technology, developing targeted therapies and assisting in the drug development pipeline of novel therapies for companies globally.
www.claritypharmaceuticals.com
Media Contact
Dr Alan Taylor
Executive Chairman
Ph: +61 (0)413 871 165
E: ataylor@claritypharm.com
